Combino Pharm: Alcoholic Clorhexidine Coloured and Aqueous Clorhexidine Transparent
Combino Pharm was founded in 1996 and since then has been devoted to developing and marketing generic medicines for both the retail and hospital markets.
Combino Pharm belongs to Corporación Medichem, a privately held group of companies active in the chemical and pharmaceutical business through its two own subsidiaries, Medichem and Combino Pharm.
The opening of Combino’s own production plant in Malta in 2006, approved by the health authorities in the EU, allowed the company to improve its flexibility and customer-orientated services, and opened new opportunities not only in contract manufacturing but also in supplying products manufactured in the EU.
Generic product market share from day one
It is a well-known fact among companies in the generic product market that being the first generic to arrive on the market is likely to be the main key factor to success in launching a new product.
Combino Pharm Malta
The strategic location of the Combino Pharm manufacturing plant in Malta offers this possibility to our clients. It allows them to launch new products on the market months before other competitors, enabling them to participate in the market from day one. Being the first is without a doubt the key to being the leader.
Solid oral dosage manufacturing plant
Combino Pharm Malta is a pharmaceutical production plant specialising in solid oral dosage forms, with facilities that occupy an approximate surface area of 6,600m² that have been designed and built according to European environmental and quality standards (EMEA).
The plant is equipped with cutting-edge technology and implements the six-sigma concepts throughout the production process allowing for efficient and flexible service.
The plant is authorised for the production and packaging of solid oral dosage forms, including Investigational Medicinal Products (IMP), and complies with the current standards of Good Manufacturing Practices (GMPs).
Contract manufacturing services
Teamwork among pharmaceutical experts at corporate level and those from the manufacturing plant ensure that the whole project, from the supply of active ingredients (API) to the commercial launch, can be managed to meet the dates that have been established and agreed upon by both parties.
Our team also incorporates experience and know-how in technology transfer, the development and control process and the production quality guarantee. We also receive ongoing assistance from specialists in intellectual property, registration, logistics, planning, engineering and purchasing.
Generic pharmaceutical product manufacturing capabilities
Combino Pharm Malta manufactures and prepares pharmaceutical products for various prestigious international laboratories. Its capabilities include:
- Manufacture of products in solid oral dosage form
- Tablets: coated / uncoated, immediate or modified release
- Hard shell capsules: powders, immediate release beads, modified release beads, granules
- Blister packaging
- Pharmaceutical contract support services
- Pharmaceutical product development
Contract development services
Combino Pharm, through its R&D department, also offers pharmaceutical product development, including:
- Complete patent evaluation, covering the active ingredient, intermediates, chemical routes and FDF
- Characterisation of the reference product, US and/or EU
- Formulation development of solid oral dosage forms and injectables
- Development process from formulation to validation
- Development of analysis and validation method
- Production of materials for clinical trials
- Stability and quality control tests (QC)
Our team also incorporates experience and know-how in production, quality control and guarantee and also receives ongoing assistance from specialists in intellectual property, registration, logistics, planning, engineering and purchasing.
Novo Nordisk broke ground for its new diabetes active pharmaceutical ingredients (DAPI) production facility in Clayton, North Carolina, on 28 March 2016.
Combino Pharm presents a new business opportunity with the product Zoledronic Acid (Ready to Use RTU).
Combino Pharm presents a new business opportunity with the product Tobramycin for inhalation.
Combino Pharm presents a new business opportunity with the product Memantine.
As always, Combino Pharm will be present at the CPhI, which this year is being held in the city of Madrid from 9 to 11 October. Combino Pharm will be delighted to welcome you to their stand 7F17.
Combino Pharm's R&D facilities are based in Sant Joan Despí, Barcelona, with an R&D Center of 1,600m², including a complete lab exclusively dedicated to formulation and process design and another exclusively dedicated to analytical development.
Combino Pharm has released a new, free-to-download white paper entitled 'Combino Pharm: Alcoholic Clorhexidine 2% Coloured and Aqueous Clorhexidine 2% Transparent'. Alcoholic Clorhexidine 2% is a tinted preoperative antiseptic used for disinfection of the skin before minor o
Besides contract manufacturing Combino Pharm Malta also offers primary and secondary packaging services and QC services for the EU market, allowing the added advantage of early entries. We are able to perform hot (for example, PVC, PVdC, Aclar) and cold (for example, Alu/Alu) forming a
As always, Combino Pharm will be present at the CPhI, which this year is being held in the city of Paris from 5 to 7 October. We will be delighted to welcome you to our stand, 5K20. You can also meet Combino Pharm in Barcelona during the EuroPLX meeting that will be held from 8 to 9 November. We